Abstract
Intradermal injections of botulinum toxin type A (BTX-A) have been used successfully to treat patients with primary palmoplantar hyperhidrosis (PPH). However, problems with local injections of BTX-A for palmar hyperhidrosis include injection pain and reduced palmar muscle strength. This case series describes three patients with PPH. Patients were followed up for 3 months and assessed using the minor iodine starch test and the visual analog scale (VAS). Over two sessions within a 2-week interval, all patients received treatment on one palm, while the other palm served as the untreated control. Treated palms received fractional CO2 laser therapy and immediate post-operative topical application of BTX-A solution for a total of 50 units. Sweat production was assessed based on the size of the sweat-producing area (measured by the minor iodine starch test) and subjective assessment of sweat production using the visual analog scale (VAS) at baseline, 2 weeks after the first treatment, and 1, 2, and 3 months after the second treatment. In the BTX-A-treated palm, the decrease in the mean sweat production was 51.6% at 2 weeks after the first treatment, and 88.5%, 67.8%, and 52.9%, at 1, 2, and 3 months after the final treatment when compared to the baseline. In the untreated palms, the decrease in the mean sweat production was 2% on all follow-ups when compared to the baseline. No adverse effect was observed in any patient. Fractional CO2 laser is a safe technique for BTX-A delivery on the palm area and is demonstrated to be safe and effective in decreasing sweat secretion of hyperhidrosis palm.
References
Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 134(3):301–304
Haedersdal M, Erlendsson AM, Paasch U, Anderson RR (2016) Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: a critical review from basics to current clinical status. J Am Acad Dermatol 74(5):981–1004
Naumann M, Lowe NJ, Kumar CR, Hamm H (2003) Hyperhidrosis clinical investigators G. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 139(6):731–736
Chow A, Wilder-Smith EP (2009) Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 160(3):721–722
Mahmoud BH, Burnett C, Ozog D (2015) Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO2 laser. Dermatol Surg 41(Suppl 1):S75–S81
Manuskiatti W, Iamphonrat T, Wanitphakdeedecha R, Eimpunth S (2013) Comparison of fractional erbium-doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatol Surg 39(1 Pt 1):111–120
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Yes (Siriraj Institutional Review Board COA no. Si 040/2017).
Informed consent [optional]
All patients signed.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Junsuwan, N., Manuskiatti, W., Phothong, W. et al. Fractional CO2 laser-assisted Botulinum toxin type A delivery for the treatment of primary palmar hyperhidrosis. Lasers Med Sci 36, 233–236 (2021). https://doi.org/10.1007/s10103-020-03064-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-020-03064-5